Drugs / TPN-672
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03931668 | Apr 2019 → Oct 2020 | pseudohypoparathyroidism type 1A | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05192304 | Feb 2022 → Mar 2023 | schizophrenia | Jiangsu Kanion Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPN-672 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05192304 ↗ |
| Known as | TPN-672 maleate tablet | “TPN-672 maleate tablet” NCT03931668 ↗ |